Journal of Crohn s and Colitis · 2010 · 337 citations · 60 references
MedicineImmunologyPharmacologyImmunopathologyImmunopharmacologyInflammationCytokine BiologyGastrointestinal InflammationImmune-mediated Inflammatory DiseasesInflammatory Bowel DiseaseInflammatory Disease PharmacotherapyInflammatory SignalingAnti-inflammatory TherapeuticsInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease PathogenesisInflammatory Bowel Disease PathophysiologyInflammatory Bowel Disease TherapyInflammatory Mediator Pathways
The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
60
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts, William J. Sandborn, Brian G. Feagan et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text